← Browse by Condition
Medical Condition
marginal zone lymphoma
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 1, Phase 2, Phase 3
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — marginal zone lymphoma Clinical Trials
How many clinical trials are currently recruiting for marginal zone lymphoma?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for marginal zone lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for marginal zone lymphoma?
marginal zone lymphoma research spans Phase 1 (2 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a marginal zone lymphoma clinical trial?
Eligibility criteria for marginal zone lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 4
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07225439 Phase 1
Recruiting
Enrollment
15 pts
Location
United States
Sponsor
Paolo Caimi, MD
NCT06510309 Phase 2
Recruiting
Enrollment
33 pts
Location
United States
Sponsor
Gottfried von Keudell, MD PhD
NCT06563596 Phase 2
Recruiting
Enrollment
71 pts
Location
United States
Sponsor
Reid Merryman, MD
NCT05326308
Recruiting
Enrollment
845 pts
Location
Austria, Germany
Sponsor
iOMEDICO AG
NCT06006117 Phase 3
Recruiting
Enrollment
260 pts
Location
Belgium, France, Ger...
Sponsor
The Lymphoma Academic Research...
NCT04186520 Phase 1, Phase 2
Recruiting
Enrollment
100 pts
Location
United States
Sponsor
Medical College of Wisconsin
NCT04883437 Phase 2
Recruiting
Enrollment
49 pts
Location
United States
Sponsor
Emory University
Related Conditions
follicular lymphoma (4) non hodgkin lymphoma (2) diffuse large b cell lymphoma (2) chronic lymphocytic leukemia (2) mantle cell lymphoma (2) lymphoma (2) b cell non hodgkin lymphoma (1) high grade b cell lymphoma (1) primary mediastinal large b cell lymphoma (1) small lymphocytic lymphoma (1) mzl (1) relapsed lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology